Earnings call transcript: Arcadia Biosciences sees Q1 2025 revenue rise 22%
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While the Zola brand shows strong sales growth and distribution expansion, gross margins are declining, and the company is transitioning to a single product line. Although the cash position is healthy, regulatory issues and unclear management responses in the Q&A create uncertainty. The revenue guidance is stable but not growing, and the completion of a key transaction is delayed. These factors suggest a neutral stock price movement in the near term.
Key Financial Performance
Total Revenues $1,200,000 (22% increase year-over-year) - Driven by strong Zola sales, which increased 90% year-over-year.
Zola Sales Increased 90% year-over-year - Primarily driven by new distribution gains, which increased 70% compared to the same period last year.
Cost of Revenues $680,000 (45% increase year-over-year) - Reflects increased sales volume.
Gross Margin Rate 43% (decrease from 52% year-over-year) - Expected to trend toward the low 30% range as the company transitions to a single product line.
Selling, General and Administrative Costs $1,700,000 (Reduction from $2,100,000 year-over-year) - Included nearly $500,000 in transaction-related fees.
Research and Development Costs $0 (compared to $6,000 in Q1 of last year) - Reflects strategy to minimize new investment.
Gain on Sale of Intangible Assets $750,000 - Resulted from the sale of wheat patents and regaining control of a legacy soy patent.
Net Income Impact from Patent Control $1,000,000 reduction in non-current liabilities - Due to the elimination of royalty obligations associated with the soy patent.
Cash Position $3,200,000 (decrease from $4,200,000 at the start of the year) - Cash consumption included ongoing M&A expenses.
Accounts Receivable $1,600,000 (increase from $1,200,000 at the start of the year) - Driven by the sale of patent assets and recovery of previously reserved receivables.
Inventory $1,300,000 (increase from $900,000 at the start of the year) - Reflects growth in Zola revenues and preparation for the spring/summer selling season.
Promissory Note Receivable Scheduled to receive approximately $2,500,000 in Q2 - Represents the first repayment of principal and interest from the sale of GoodWheat assets.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Zola Sales Growth: Zola coconut water sales increased 90% year over year in Q1 2025, driven by a 70% increase in new distribution.
New Product Launches: Launched new flavors (lime and pineapple) last year; pineapple sales in 2025 have already surpassed total sales from last year.
New Product Innovations: Working on new product offerings that provide a twist on traditional coconut water, with positive feedback from major customers.
Market Expansion: Zola's distribution has expanded significantly, with new customer accounts and discussions with distributors representing over 50% of current customer base.
Inventory Positioning: Replenished inventory ahead of the beverage season, mitigating potential impacts from tariffs.
Cost Control: Implemented tight cost controls resulting in a 16% year over year reduction in operating expenses.
Gross Margin Performance: Gross margins exceeded 30% for nine consecutive quarters, with a current rate of 43%.
Exit Legacy Business: Completed a transaction to regain rights to soy patents, eliminating a $1,000,000 liability and streamlining operations.
Pending Business Combination: Business combination with Roosevelt Resources is on track for completion by August 15, 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The pending business combination with Roosevelt Resources has faced delays, with the timeline for completion pushed back from May 15 to August 15, 2025, due to the need for both companies to prepare financials and respond to SEC comments.
Supply Chain Challenges: The company anticipates that the 10% baseline tariff that went into effect in early April 2025 will have little to no impact on Q2 financial results, as they have identified cost-saving opportunities to offset the impact. However, they have developed mitigation plans should the need arise.
Economic Factors: The company is experiencing strong sales growth in the coconut water category, which is outpacing many other beverage categories. However, they acknowledge that uncertainties could affect the overall timing of the pending business combination.
Legacy Business Risks: Arcadia is working to exit its legacy AgTech business and has eliminated a $1,000,000 contingent liability from its balance sheet by regaining rights to a soy patent. They are also exploring options to alleviate future liabilities related to a remaining tomato patent.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Zola Sales Growth: Zola sales increased 90% year over year, driven by new distribution gains.
Cost Control: Implemented tight cost controls resulting in a 16% year over year reduction in operating expenses.
Intellectual Property Monetization: Significant progress in monetizing intellectual property, including a transaction with BioSeries.
New Product Innovations: Working on new product offerings expected to launch early next year.
Pending Business Combination: Business combination with Roosevelt Resources is on track to be completed towards the end of summer.
Revenue Expectations: Total revenues for Q1 were approximately $1,200,000, a 22% increase year over year.
Gross Margin Expectations: Expect gross margin rates to trend toward the low 30% range.
Future Cash Receipts: Scheduled to receive approximately $2,500,000 from a note receivable in Q2.
Operating Expenses: Operating expenses are near their lowest level in ten years.
Impact of Tariffs: Expect tariffs to have little to no impact on Q2 financial results.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash from Patent Sale: Arcadia received $750,000 in cash from the sale of its remaining wheat patents.
Elimination of Contingent Liability: Regaining control of the legacy soy patent allowed Arcadia to eliminate a $1,000,000 contingent liability from its balance sheet.
Future Royalties: The transaction eliminated future royalty obligations associated with the technology.
Cash Position: Arcadia ended Q1 with $3,200,000 in cash.
Note Receivable: Arcadia is scheduled to receive approximately $2,500,000 as the first repayment of principal and interest from a promissory note.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you quantify for us any successes that you have to date and then maybe at least directionally talk about the magnitude of the pipeline that you think is still out there for potential expansion later this year?
A:In terms of the size of the pipeline, it’s probably about half of our current distribution, which is in the neighborhood of 3,500 stores.
Q:Do you expect that to the momentum that you have here to be reflected still in the 2025 financials or is that going to be more of a ’26 type event?
A:Most of those awards that we are looking towards would have an impact on 2025.
Q:Do you guys anticipate that there’s any commercial value there? Or is it similar to the patent that you just got back from BioSeries that you simply just want to get it back so you can retire it?
A:There is potentially commercial value, but not for Arcadia. It is licensed to a third party.
Q:Do you expect to have that in hand here within this within the second quarter? Or is that something that could get pushed out into the third?
A:Yes, scheduled for receipt in Q2.
Q:Review of Unclear Management Responses
A:Management's response regarding the commercial value of the remaining patent was vague, indicating potential value but lacking specifics on what that might entail or how it would affect Arcadia's operations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arcadia party
BioSeries TJ
Congratulations queue
Officer TJ
Officer receipt
Officer summary
Officer term
Officer type
Officer value
Schafer President
Schafer closing
Street Lake
Street account
Street kind
Street question
Street queue
TJ Schafer
account couple
account distribution
account number
advantage effort
ag biotech
award Lake
biotech patent
combination remark
commercialization explore
conversation year
couple month
couple question
customer distributor
date expand
date magnitude
distribution date
distribution lag
distribution neighborhood
liability
size
success
RKDA Transcript
Earnings call transcript: Arcadia Biosciences sees Q1 2025 revenue rise 22%
Unknown5-8
The earnings call presents a mixed picture. While the Zola brand shows strong sales growth and distribution expansion, gross margins are declining, and the company is transitioning to a single product line. Although the cash position is healthy, regulatory issues and unclear management responses in the Q&A create uncertainty. The revenue guidance is stable but not growing, and the completion of a key transaction is delayed. These factors suggest a neutral stock price movement in the near term.
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2024 Earnings Call Transcript
Unknown3-22
Despite strong Zola sales growth and distribution expansion, the company faces significant challenges such as missing EPS expectations, declining cash reserves, and increased SG&A expenses. The lack of forward guidance and unclear management responses in the Q&A further add to investor uncertainty. The pending transaction with Roosevelt Resources and the decline in GLA oil sales also pose risks. These factors are likely to result in a negative stock price movement.
Arcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call Transcript
Neutral3-20
Arcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call Transcript
Neutral3-20
RKDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
